Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes
Authors Tan Q, Zhang J, Wang, Yang, Li, Xiong, Wu, Zhao, Wang, Yin
Received 12 May 2012
Accepted for publication 31 May 2012
Published 23 July 2012 Volume 2012:7 Pages 3929—3938
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Qun-You Tan,1,* Jing-Qing Zhang,2,* Na Wang,3,* Hong Yang,4 Xiaoling Li,5 Hua-Rong Xiong,2 Jian-Yong Wu,2 Chun-Jing Zhao,3 Hong Wang,2 Hua-Feng Yin2
1Department of Thoracic Surgery, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 2Medicine Engineering Research Center, Chongqing Key Laboratory of Biochemical & Molecular Pharmacology, Chongqing Medical University, Chongqing, 3School of Pharmacy, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 4School of Pharmacy, Medical College of Soochow University, Soochow, People's Republic of China; 5TJ Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA, USA
*These authors contributed equally to this work
Objective: Previous studies on various enzymosomes (functional lipid vesicles encapsulating an enzyme) have been mostly carried out in vitro and have focused on preserving catalytic activity and improving the stability of the enzyme. Until now, few studies have focused on their in vivo fate. Similarly, although we have previously reported the increased in vitro uricolytic activity (about 2.2 times higher than that of free uricase, or three times higher than that of PEGylated uricase, Puricase®, under physiological pH and temperature) and improved stability of the novel alkaline enzymosomes (functional lipid vesicles encapsulating uricase from Candida utilis: uricase-containing lipid vesicles, UOXLVs), it is still necessary to study the biological properties and hypouricemic effects of UOXLVs in vivo.
Methods: The enzyme kinetics, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary safety of UOXLVs were evaluated.
Results: The Michaelis constant (Km) value of the UOXLVs was slightly lower than that of the free enzyme. The enzyme release from the UOXLVs lasted over 12 hours and their circulation half-life was about sevenfold longer than that of the free uricase. Meanwhile, the UOXLVs had a 22-fold increase in the area under the curve compared with the free uricase. Furthermore, it took less than 3 hours for the UOXLVs to lower the plasma uric acid concentration from a high to a normal level, compared with 6 hours for the free uricase. In addition, the UOXLVs had much less immunogenicity than free uricase and were well tolerated by all animals throughout the observation period.
Conclusion: The UOXLVs markedly improved the biological properties and enhanced the hypouricemic effects of uricase in vivo.
Keywords: biological properties, hypouricemic effect, uricase, alkaline enzymosomes, in vivo
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]